Analytical Comparison of the Originator Granulocyte-colony Stimulating Factor Filgrastim and its Biosimilars.

CONCLUSIONS: This study shows that a high level of similarity is maintained among originator and three biosimilar filgrastims up to 5 years from their first registration in the EU.
PMID: 30417773 [PubMed - as supplied by publisher]

Source: Current Pharmaceutical Design - November 9, 2018 Category: Drugs & Pharmacology Authors: Orlik G, Khan MA, Grieb P Tags: Curr Pharm Des Source Type: research